CytomX Therapeutics (CTMX) EPS (Basic) (2016 - 2025)
Historic EPS (Basic) for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$0.09.
- CytomX Therapeutics' EPS (Basic) fell 22857.14% to -$0.09 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.41, marking a year-over-year increase of 14117.65%. This contributed to the annual value of $0.38 for FY2024, which is 390000.0% up from last year.
- According to the latest figures from Q3 2025, CytomX Therapeutics' EPS (Basic) is -$0.09, which was down 22857.14% from $0.27 recorded in Q1 2025.
- In the past 5 years, CytomX Therapeutics' EPS (Basic) ranged from a high of $0.27 in Q1 2025 and a low of -$0.53 during Q4 2021
- Its 5-year average for EPS (Basic) is -$0.15, with a median of -$0.08 in 2024.
- Data for CytomX Therapeutics' EPS (Basic) shows a peak YoY increase of 220000.0% (in 2024) and a maximum YoY decrease of 30000.0% (in 2024) over the last 5 years.
- CytomX Therapeutics' EPS (Basic) (Quarter) stood at -$0.53 in 2021, then skyrocketed by 75.62% to -$0.13 in 2022, then surged by 107.69% to $0.01 in 2023, then soared by 2200.0% to $0.23 in 2024, then crashed by 139.13% to -$0.09 in 2025.
- Its last three reported values are -$0.09 in Q3 2025, $0.27 for Q1 2025, and $0.23 during Q4 2024.